Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments

You may also be interested in...



Emerging Markets Slowdown Trips Up Lilly’s 2014 Revenue Estimates

Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.

As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader

With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.

Lessons From Galvus: Novartis Teams Up With India’s Lupin To Market COPD Drug Onbrez

Novartis will compete against market leader Cipla to make a dent in the emerging Indian COPD space.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel